This inventor holds 1 USPTO granted patent. Top assignees: Denka Company Limited, National Institute of Infectious Diseases, The Kitasato Institute. Active years: 2022.
Company Filing History:
1 out of 385 
1 out of 37 
1 out of 102 
Years Active: 2022
Title: Megumi Mano: Innovator in Norovirus Vaccine Development
Introduction
Megumi Mano is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of vaccine development, particularly focusing on norovirus. Her innovative work has led to the creation of a unique vaccine that addresses critical challenges in immunization.
Latest Patents
Megumi Mano holds a patent for a composite polypeptide monomer and an aggregate of said composite polypeptide monomer having cell penetration function. This patent also includes a norovirus component vaccine designed for subcutaneous, intradermal, percutaneous, or intramuscular administration. The invention aims to provide a vaccine that can effectively immunize target cells, utilizing a molecular needle as an active ingredient. The associated product includes a hexamer formed through bonding of two molecules of a trimer of a molecular needle, which is represented by a specific formula. This innovative approach enhances the vaccine's efficacy and delivery.
Career Highlights
Throughout her career, Megumi Mano has worked with notable organizations, including Denka Company Limited and The Kitasato Institute. Her experience in these institutions has allowed her to refine her research and contribute to advancements in vaccine technology.
Collaborations
Megumi has collaborated with esteemed colleagues such as Kengo Yoshikawa and Reiko Todaka. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas in the field of vaccine research.
Conclusion
Megumi Mano's contributions to norovirus vaccine development exemplify her dedication to advancing medical science. Her innovative patent and collaborative efforts highlight her role as a key figure in the field. Her work continues to pave the way for future advancements in immunization technology.